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In 2009, a novel lyssavirus (subsequently named Ikoma lyssavirus, IKOV) was detected in the
brain of an African civet (Civettictis civetta) with clinical rabies in the Serengeti National Park of
Tanzania. The degree of nucleotide divergence between the genome of IKOV and those of other
lyssaviruses predicted antigenic distinction from, and lack of protection provided by, available
rabies vaccines. In addition, the index case was considered likely to be an incidental spillover
event, and therefore the true reservoir of IKOV remained to be identified. The advent of sensitive
molecular techniques has led to a rapid increase in the discovery of novel viruses. Detecting viral
sequence alone, however, only allows for prediction of phenotypic characteristics and not their
measurement. In the present study we describe the in vitro and in vivo characterization of IKOV,
demonstrating that it is (1) pathogenic by peripheral inoculation in an animal model, (2)
antigenically distinct from current rabies vaccine strains and (3) poorly neutralized by sera from
humans and animals immunized against rabies. In a laboratory mouse model, no protection was
elicited by a licensed rabies vaccine. We also investigated the role of bats as reservoirs of IKOV.
We found no evidence for infection among 483 individuals of at least 13 bat species sampled
across sites in the Serengeti and Southern Kenya.
INTRODUCTION
The discovery of novel viruses has flourished with the
advent of highly sensitive molecular detection techniques
(Bexfield & Kellam, 2011; Lipkin & Firth, 2013). These
include metagenomic studies of the viral flora of healthy
animals aimed at predicting transmission risks to other
species, and the detection of pathogens in clinical samples
and excreta for diagnosis (Bodewes et al., 2013; Ge et al.,
2012; Li et al., 2011; Phan et al., 2011; van den Brand et al.,
2012). Such studies provide valuable information on the
presence and variability of viral pathogens in different
animal populations. However, the detection of viral nucleic
acid alone provides limited information on the zoonotic
and pathogenic potential of such viruses.
Recent expansion of the genus Lyssavirus, within the family
Rhabdoviridae, provides an example of rapid increase in the
number of novel viruses identified, with the number
of lyssavirus species doubling in the past 10 years. There
are 12 lyssavirus species classified by the International
Committee on Taxonomy of Viruses, with two awaiting
classification (Dietzgen et al., 2011) and genetic evidence
for a further putative lyssavirus detected in Spain (Are´chiga
Ceballos et al., 2013). Lyssaviruses are divided into at least
two phylogroups, based on genetic and antigenic distance
(Badrane et al., 2001; Evans et al., 2012; Hanlon et al., 2005;
Horton et al., 2010; Table S1, available in the online
Supplementary Material). All lyssaviruses cause rabies,
which remains untreatable once clinical signs develop
(Johnson et al., 2010) with a near 100% fatality rate.
Therefore, prevention of disease relies upon pre- and post-
exposure prophylaxis through administration of vaccine and
immune globulin. All licensed vaccines and immune globulin
Two supplementary tables and supplementary methods are available
with the online version of this paper.
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treatments are based on inactivated preparations or anti-
bodies directed against ‘classical’ rabies virus (RABV). These
preparations elicit protective immunological responses to all
RABV variants tested, but have variable efficacy against
several other lyssaviruses (Badrane et al., 2001; Brookes et al.,
2005a; Hanlon et al., 2005; Lodmell et al., 1995). Although
difficult to quantify, this variation is related to antigenic
distances of such lyssaviruses from vaccine strains (Badrane
et al., 2001; Evans et al., 2012; Hanlon et al., 2005; Horton
et al., 2010). A strong immunological response to standard
rabies vaccine has been shown to protect against lyssaviruses
that are classified within phylogroup I, but not against viruses
classified within other phylogroups (Fooks, 2004).
In 2009, an African civet (Civettictis civetta), with clinical
signs of rabies, was killed in the Serengeti National Park
(SNP), Tanzania, after biting a child. The child received
appropriate wound care and post-exposure rabies prophy-
laxis and remained healthy. Direct antigen-detection tests on
brain samples from the civet confirmed infection with a
lyssavirus, and genetic analysis demonstrated that the
causative agent (Ikoma lyssavirus, IKOV) was highly
divergent from all lyssaviruses characterized previously
(Marston et al., 2012a, b). This finding was particularly
significant as dogs are not permitted in the SNP, and the
area of the park where the civet was encountered had been
free from canine rabies for over 8 years (Lembo et al., 2008).
Prediction of antigenic distance and by extrapolation, degree
of protection, provided by rabies vaccine strains using
sequence data alone is not precise, but the degree of genetic
divergence suggested that currently available vaccines would
not be likely to be able to confer protection against IKOV
(Evans et al., 2012; Horton et al., 2010).
The African civet, a solitary scavenger, does not fill the
ecological niche nor have the population dynamics typical of
a carnivore rabies host (Cleaveland & Dye, 1995; Estes,
1992). The few published reports of rabies in civets have
been either dog- or mongoose-associated RABV variants,
suggestive of spillover rather than maintenance of infection
(Sabeta et al., 2008). Despite dogs being responsible for the
majority of human rabies cases worldwide, a variety of
RABV lineages and numerous diverse lyssavirus species have
been detected in wildlife, and particularly in a range of bat
species (Banyard et al., 2011; Hayman et al., 2012; Kuzmin
et al., 2010). Antibodies to a phylogenetically related
lyssavirus, West Caucasian bat virus (WCBV), have been
detected in Miniopterus spp. bats in Kenya close to the
border with Tanzania (Kuzmin et al., 2008a), but there are
no published studies showing evidence for lyssavirus
antibodies in bats in the SNP. Therefore, with evidence for
bat reservoirs for closely related viruses, it is possible that the
natural host and reservoir for IKOV is a bat species.
The detection of genetic material from a new virus causing
rabies in a potential spillover host, with no known
reservoir, requires further investigation. Here we describe
the isolation and characterization of viable IKOV in
vivo and in vitro, assess the degree of serological
cross-neutralization of IKOV with RABV and WCBV,
and assess the efficacy of rabies vaccination against IKOV
in an animal model. We also present results of surveillance
for IKOV in bats living in close proximity to the location of
the index case.
RESULTS
In vitro characterization
IKOV was not easily isolated from clinical material. Repeated
blind passage of civet brain homogenate in neuroblastoma cell
culture failed to amplify viable virus. IKOV was initially
isolated through intracranial (IC) inoculation of 4-week-old
CD-1 mice and stocks of virus were then generated by six
serial passages in murine fibroblast (baby hamster kidney,
BHK-21) cells. The fluorescent antibody test (FAT) was
performed on brain smears post-mortem. Viral antigens were
detected using FITC-conjugated anti-rabies nucleocapsid
protein antibodies. This preparation of antibodies has
demonstrated high sensitivity and specificity in detecting
lyssaviruses (Robardet et al., 2012). Virus titres at passage five
(104.42, TCID50 ml
21) and passage six (104.8 TCID50 ml
21)
were comparable to those seen with other lyssaviruses
(Brookes et al., 2005a; Horton et al., 2010; Koraka et al., 2012).
A modified fluorescent antibody virus neutralization
(mFAVN) test was used to assess the degree of cross-neutral-
ization between IKOV and other lyssaviruses (Brookes et al.,
2005b; Cliquet et al., 1998). Sera from four humans and ten
dogs vaccinated with commercial rabies vaccines demon-
strated negligible levels of cross-neutralization against IKOV
(Table 1). Three of these individuals had exceptionally high
reciprocal antibody titres against RABV (Challenge Virus
Standard, CVS) of over 1 : 30 000, and yet had reciprocal
titres of less than 1 : 8 against IKOV, indistinguishable from
negative controls and therefore effectively negative. In
addition, neat human rabies immune globulin (HRIG), at
a concentration of 270 IU ml21, showed no detectable
neutralization of IKOV. Sera from mice inoculated with
IKOV that showed reciprocal antibody titres of 1 : 27 to
1 : 420 against IKOV failed to neutralize CVS in standard
FAVN tests. Furthermore, rabbit serum with a neutralizing
antibody titre of over 1 : 1000 against WCBV failed to
neutralize IKOV (Table 1). This lack of detectable cross-
neutralization precluded accurate positioning of IKOV on
an antigenic map developed previously (Horton et al., 2010).
In vivo pathogenesis
All mice inoculated IC with 0.03 ml tissue culture passaged
IKOV at high dose (104.8 TCID50 ml
21) or a 10-fold
dilution (10 3.8 TCID50 ml
21) succumbed to challenge with
an incubation period of between 4.5 and 6 days, with no
apparent dose effect. There was, however, a detectable dose
effect (albeit not statistically significant at the 95% level)
for the intramuscularly (IM) challenged mice, with 5/5 of
the mice challenged IM with 0.03 ml IKOV at 104.8 TCID50
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ml21 succumbing between 6.5 and 9 days, but only 2/5 of
the group receiving IKOV at 10 3.8 TCID50 ml
21
succumbing, with incubation periods of 7 and 11 days
(Fischer’s exact test, P50.08; Fig. 1). The remaining three
mice inoculated IM with the lower dose had no detectable
lyssavirus antigens in the brain post-mortem, but had
seroconverted when subjected to euthanasia at 28 days
(Table 1). Prodromal clinical signs were similar to those
recorded for other lyssaviruses in mice, including reduced
appetite, ruffled fur and hunched posture (Healy et al.,
2013). Mice then progressed to either hind limb paralysis,
or hyperexcitability and convulsions, with a predominance
of the latter, and were subjected to euthanasia.
Pathology
Mice inoculated with IKOV and subject to euthanasia at a
clinical score of 2 to 3 had developed non-suppurative
encephalitis (Fig. 2a). The inflammatory changes were very
mild, with occasional perivascular cuffing but without
notable gliosis or degenerative changes in neurons. IKOV
antigens were observed using immunohistochemistry
(IHC) in the perikaryon and neuropil in all brain regions
examined, with the majority of staining in the medulla and
only rare and dispersed antigens in the cortex and thalamus
(Fig. 2b).
Vaccine challenge experiments
Nineteen mice were vaccinated with one dose of a
commercial rabies vaccine, and 18 of these had serocon-
verted against RABV by day 21 (Titre range 0.70–256 IU
ml21), confirming an adequate response to vaccination.
Mice vaccinated under identical conditions were previously
demonstrated to be protected against IC challenge with
RABV (Brookes et al., 2005a). All 19 mice challenged IC
with IKOV in a modified National Institutes of Health
(NIH) test developed rabies, as did all the unvaccinated
controls. The presence of IKOV antigens and RNA was
confirmed in the brains of challenged mice.
Genetic characterization
Comparison of the full genome of IKOV with the full
genome of representatives of other lyssaviruses allows
interpretation of genetic relationships among the lyssa-
viruses (Fig. 3). Analysis of the full genomes supports
the previously reported relationship of WCBV and IKOV.
Lagos bat virus (LBV), Shimoni Bat virus (SHIBV) and
Mokola virus (MOKV), all previously characterized as
phylogroup II, comprise a strongly supported separate
monophyletic group. The European bat lyssaviruses
have separate ancestors. European bat lyssavirus type-1
(EBLV-1) shares a common ancestor with Duvenhage
virus (DUVV) and Irkut virus (IRKV), separate from
the ancestor common to European bat lyssavirus type-2
(EBLV-2) and the remaining lyssavirus species [RABV,
Aravan virus (ARAV), Khujand virus (KHUV), Bokeloh
bat lyssavirus (BBLV) and Australian bat lyssavirus
(ABLV)]. IKOV and WCBV form a monophyletic
group outside of the phylogroup I and phylogroup II
lyssaviruses with significant bootstrap support, although
they are separated by long genetic distance (63.4%
nucleotide identity for the concatenated coding gene
sequences).
Sampling of bats in Africa for antibodies to IKOV
The common and ubiquitous free-tailed bats (Chaerephon
pumilus) in the immediate vicinity of the index IKOV case
in the SNP were roosting in the roof space of the few
human dwellings, used by park employees and research
scientists. These were therefore the priority for sampling in
Tanzania, and were the only species encountered during
sampling in SNP in 2012. Sera were available from 25 of
these free-tailed bats (C. pumilus) sampled within SNP, and
in two settlements in close proximity to the north-western
boundary of the SNP. Two other species (Hipposideros sp.,
n516, and Nycteris sp., n51) were also sampled in these
settlements. In Kenya, 441 individuals from at least 10
Table 1. Cross-neutralization of sera from rabies vaccinated
humans and animals against IKOV
Neutralizing antibody titres against RABV (Challenge virus standard,
CVS) and IKOV in reciprocal 50% end point titres. International
units (IU) are given for rabies by comparison to a standard control
(not applicable to IKOV). Mice 3, 4 and 5 were inoculated IM with
IKOV at 103.8 TCID50 ml
21 and survived. Rabbit 821 is rabbit anti-
WCBV serum with a reciprocal titre of 1448 against WCBV. ND, not
done.
Virus
CVS
(100 TCID50)
IKOV
(100 TCID50)
Sample ID IU ml”1 Reciprocal titre Reciprocal titre
HUMAN - 1 23 959 ,8
HUMAN - 2 31 1 263 ,8
HUMAN - 3 1 093 34 092 ,8
HUMAN - 4 1 093 34 092 ,8
DOG 1 53 1 263 ,8
DOG 2 41 960 ,8
DOG 3 1 094 25 904 ,8
DOG 4 122 2 878 ,8
DOG 5 365 8 635 ,8
DOG 6 1 16 ,8
DOG 7 1 094 34 109 ,8
DOG 8 364 11 364 ,8
DOG 9 14 421 ,8
DOG 10 41 1 263 ,8
HRIG 270 ND ,16
Mouse 3 ,0.2 ,16 27
Mouse 4 ,0.2 ,16 420
Mouse 5 ND ND 81
Rabbit 821 ,0.2 ,16 ,8
Characterization of Ikoma lyssavirus
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different bat species were caught in multiple locations
during 2011, in the framework of the Global Disease
Detection Program of the US Centers for Disease Control
and Prevention (CDC) (Table S2). These included 229
Miniopterus spp., of which 48 neutralized WCBV (titre
range 1.3–3.1 log10 ED50). All 483 of these sera from
Tanzania and Kenya failed to show any neutralizing activity
against IKOV (see Table S2 and Methods provided in the
online Supplementary Material).
DISCUSSION
The discovery of a novel lyssavirus (IKOV) causing rabies
in an African civet, in a wildlife-rich area with potential for
wildlife–human interaction, required further investigation
to assess its public and animal health significance. Here, we
have demonstrated that peripheral pathogenicity of IKOV
is comparable to that of RABV in a rodent model. The
virus is antigenically distinct to all other lyssaviruses, and
vaccination with rabies vaccine produced no cross-
neutralizing antibodies in humans or animals, and did
not elicit protection in an animal challenge model.
The G protein is the immunodominant lyssavirus protein,
and comparison of the G coding sequence of IKOV with
other lyssavirus species demonstrates 46–50% and 52–
55% similarity at the nucleotide and amino acid levels,
respectively (Evans et al., 2012). Previous quantitative
assessments of the effect of these genetic differences on
antigenicity suggested that 72% amino acid identity along
the G ectodomain is a threshold for efficient cross-neutral-
ization (Badrane et al., 2001), and that a 4.8% difference in
amino acid sequence identity over the ectodomain region
would cause, on average, a twofold difference in antibody
titre against a virus (Horton et al., 2010). Therefore, with
only 47% amino acid identity with CVS, we would expect
to see no cross-neutralization between RABV and IKOV.
Here we were able to confirm this hypothesis, demonstrat-
ing a complete lack of cross-neutralization in sera of
humans and animals vaccinated from rabies, even if they
demonstrated very high neutralizing titres against CVS.
Similar studies of phylogroup I lyssaviruses showed
reduced but significant neutralization of EBLVs relative
to CVS (Brookes et al., 2006; Malerczyk et al., 2009), and
even studies of the most divergent lyssavirus prior to this
discovery, WCBV, showed a limited neutralization by sera
of rabbits that had high neutralizing titres against CVS
(Hanlon et al., 2005; Horton et al., 2010). In this study, we
have demonstrated a lack of cross-neutralization between
IKOV and WCBV, despite the viruses having a mono-
phyletic relationship in phylogenetic reconstructions. Our
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Fig. 1. Survival chart showing percentage survival in days post-inoculation (p.i) for groups of five mice inoculated either
intracranially (IC) or intramuscularly (IM) with neat IKOV (104.8 TCID50 ml
”1) or a 1/10 dilution (103.8 TCID50 ml
”1). Mice not
clinically affected after 11 days were still healthy when euthanized at 28 days and negative for lyssavirus antigens post-mortem.
(a)
(b)
Fig. 2. Histopathological examination of brain from IKOV-infected
mice. (a) Perivascular cuffing in the cortex composed of few
inflammatory cells. Inflammatory changes were minimal to mild and
perivascular cuffs rare and not prominent. Image shows haema-
toxylin and eosin staining at 400 magnification. (b). IHC
demonstration of viral antigens in the medulla (brown labelling).
Image shows IHC at 400 magnification.
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observations suggest that demarcation of lyssaviruses into
phylogroups may be more complex than a comparison of
glycoprotein identity values and amount of cross-neutral-
ization as proposed initially (Badrane et al., 2001).
Crucially, HRIG at 270 IU ml21 failed to show significant
neutralization of IKOV (Table 1). In all category three
exposures, HRIG is recommended as defined by the
WHO (Anon, 2009), but these data demonstrated it is
unlikely that HRIG would be effective against IKOV. This
lack of protection afforded by rabies biologics reinforces
the value of thorough wound cleaning and antiseptic
treatment in cases of exposure to carnivores and bats
(Anon, 2009).
The current gold standard test for assessment of rabies
vaccine potency is the NIH test, which uses an IC challenge
in mice vaccinated with serial dilutions of vaccine (Wilbur &
Aubert, 1996). The test has been successfully modified for
the assessment of protection against other viruses by using a
single vaccine dilution, and mice vaccinated using this
technique have previously been protected against IC
challenge with RABV (Brookes et al., 2005a; Wilbur &
Aubert, 1996). However, all 19 mice vaccinated with
commercial rabies vaccine and challenged with IKOV
succumbed to disease, demonstrating that no protection
was conferred. These results confirm the predictions
obtained from the genetic and in vitro antigenic studies
that rabies vaccines do not elicit protection against IKOV in
mice and are therefore unlikely to provide protection in
other mammals, including humans.
Analysis of full concatenated coding gene sequences of
representative lyssaviruses showed similar topology to
previous analyses based on partial N-gene sequences and
glycoprotein sequences, suggesting that IKOV and WCBV
form a monophyletic group, albeit with deeply rooted
divergence (Evans et al., 2012; Marston et al., 2012a). One
difference seen here is that in the previous partial N-gene
analyses, MOKV, WCBV and IKOV formed a monophy-
letic group separate from LBV, which is not the case in this
full genome comparison.
Knowledge of the reservoir of zoonotic diseases is
important, to inform prevention of spillover infections.
IKOV was detected in an African civet, an unlikely reser-
voir for a lyssavirus. Civets are mostly solitary scavengers,
with presumed low contact rates (Estes, 1992). Consistent
with this ecology is the detection of varied canid and
mongoose variants of RABV in the few reported cases of
rabies in civets, suggesting that civets are spillover hosts
(Sabeta et al., 2008). No further cases caused by IKOV have
been detected, despite high levels of tourist and research-
related activity in the area that have been sufficient to
detect RABV in another wild carnivore since the index
IKOV case. This suggests that the civet case did not result
in a sustained chain of transmission. Nonetheless, a civet
reservoir cannot be ruled out definitively, so vigilance for
rabies in civets and other wild carnivore species still needs
to be maintained, including virus characterization of any
positive cases.
In light of the association of lyssaviruses with bats (Banyard
et al., 2011), attention has inevitably focused on bat
populations in and around SNP to find the reservoir of
IKOV. The IKOV-positive civet was encountered on the
edge of the Serengeti plains, with few suitable roosting
places for bats. Previous studies demonstrated up to 70%
seroprevalence of bats to various lyssaviruses (Harris et al.,
2009; Hayman et al., 2012; Kuzmin et al., 2010, 2008a, b;
Turmelle et al., 2009) but all bat sera tested in this study
were negative for antibodies to IKOV. The limited sample
LBVc LBVa
LBVb
SHIBV
WCBV
IRKV
EBLV1
DUVV
ABLV
RABV
EBLV2
BBLV
KHUV
ARAV
MOKV
1
1
1
1
1 1
1
1
11
0.6
0.5
0.7
0.9
0.9
LBVd
IKOV
Fig. 3. Neighbour-joining phylogenetic tree of
concatenated coding areas of five genes
(N+P+M+G+L) of IKOV compared to
representative lyssaviruses from all other spe-
cies (Table S1). Branches are coloured by
phylogroup: green, phylogroup one; red, phylo-
group two; and blue, uncharacterized. Boostrap
values (proportion of 1000 replicates) are given
at each node.
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size, species coverage and narrow time frame preclude
robustly ruling out IKOV infection in bats. However,
based on these data, and seroprevalence levels demon-
strated in reservoir bat populations to other lyssaviruses, it
is unlikely that IKOV was circulating in the local free-
tailed bat population at the time of sampling. However,
the presence of other bat species, the variable success of
bat capture techniques for different species, and the
possibility of long-distance bat movements, suggests that
the reservoir of IKOV is still likely to be in a bat species.
The most recently detected putative lyssavirus species,
Lleida bat lyssavirus, was detected in a Miniopterus
schreibersii bat in Spain, and is phylogenetically related
to WCBV and IKOV (Are´chiga Ceballos et al., 2013).
Miniopterus spp. bats are also a putative reservoir for
WCBV in Kenya (Kuzmin et al., 2008a). There was a
notable absence of Miniopterus spp. captured in the SNP,
despite the species being detected in large numbers in
neighbouring Kenya. All Miniopterus spp. bat sera from
Kenya were negative for IKOV antibodies, but there are at
least 12 species of Miniopterus bats described in Africa
(IUCN, 2013), and some species roost mainly in caves
and can travel long distances to feed. Sampling of cave-
dwelling bats in and around the SNP, together with
serological screening of other wildlife samples from the
SNP, would be a logical next step to investigating
potential reservoirs.
In the experimental animal model used in this study, the
incubation period, clinical signs and pathology of IKOV
infection were consistent with those caused by other
lyssaviruses (Healy et al., 2013), and these data therefore
confirm that IKOV causes rabies. The peripheral patho-
genicity of IKOV concurs with recent studies showing that
substitution at a key domain of the glycoprotein (K/
R333D) which is shared by IKOV and phylogroup II
lyssaviruses, does not result in lower peripheral patho-
genicity (Badrane et al., 2001; Kgaladi et al., 2013; Kuzmin
et al., 2010, 2008b; Markotter et al., 2008), in contrast to
initial data based on fewer isolates (Badrane et al., 2001).
These results are corroborated by the fact that IKOV
caused clinical rabies in the civet from which it was
originally isolated, and therefore has potential to cause
encephalitis in other hosts. This raises the question as to
why spillover events like this do not happen more
frequently. One obvious possibility is that they do, but
remain undetected. IKOV was identified during dedicated
studies on rabies dynamics in Tanzania, but virus
characterization is not routine in most regions of Africa,
with positive cases assumed to be RABV. Alternatively,
species constraints might limit the number of effective
spillover infections with IKOV as was suggested for other
bat lyssaviruses (Banyard et al., 2011). Continued
enhanced surveillance, including laboratory-based con-
firmation of diagnosis and virus characterization, is
necessary to assess and mitigate the public and animal
health threats posed by IKOV and other emerging viruses
(Banyard et al., 2013).
METHODS
In vitro. Civet brain material was stored frozen at the Tanzania
National Parks veterinary field laboratory in the Serengeti from 2009
until 2011 and then shipped to AHVLA for virus isolation and
characterization. Brain homogenates from the first mouse passage
were used to inoculate BHK-21 cell cultures, and the virus was
passaged to a high titre for in vivo analysis during six passages: 0.5 ml
clarified 10% mouse brain homogenate in PBS was added to 2 ml of a
BHK-21 cell suspension at 26105 cells ml21, and incubated at 37 uC
for 20 min with intermittent agitation. The infected cells were then
added to a cell culture flask with fresh Glasgow minimal essential
medium supplemented with 10% FBS and 10% tryptose phosphate
broth. Every 3–5 days the cells were disrupted using antibiotic–
trypsin–versene and transferred to a new flask with fresh media, and
uninfected cells at a 1 : 1 ratio of infected to uninfected cells. Virus
titre was assessed at passages five and six using techniques described
previously (Aubert, 1996) and calculated with the Spearman–Ka¨rber
method. Viral antigens were visualized in acetone-fixed cells by the
direct fluorescent antibody test (FAT) using standard techniques
(Dean et al., 1996) with an FITC-conjugated antibody (FITC anti-
rabies monoclonal globulin; Fujirebio Diagnostics).
A modified fluorescent antibody neutralization test (mFAVN) was
developed and optimized for IKOV using tissue culture passaged
virus supernatant (TCSN) (Horton et al., 2010). A standard quantity
of virus (100 TCID50 per 50 ml) was added to serial twofold dilutions
of serum in duplicate, with the quantity of virus checked by back-
titration on each test. Sera and virus were incubated with BHK-21
cells for 48 h before fixing in acetone and staining with FITC-
conjugated antibody (Fujirebio Diagnostics). The 50% end point
serum dilution was calculated with the Spearman–Ka¨rber method
(Aubert, 1996). Mouse serum from the second mouse passage of
IKOV was used as a positive control, and serum from uninfected mice
was used as a negative control. A panel of sera from animals and
human vaccinees, with proven high serum neutralizing antibody
levels to RABV, were tested for their ability to neutralize IKOV (Table
1). A rabbit anti-WCBV serum (rabbit 821), which neutralized
WCBV at a reciprocal titre of 1 : 1448, was also tested in the same
assay (Horton et al., 2010).
In vivo. All experimental work in animal models was undertaken
under Home Office Licence after independent ethical review. Virus
was first isolated from clinical material in 4-week-old OF1 mice, after
unsuccessful isolation attempts in cell culture despite repeated
passages using the rabies tissue culture inoculation test (RTCIT;
Marston et al., 2012a). Clarified civet brain homogenate (30 ml) was
inoculated into mice (n55) IC. Mice were monitored twice daily
using a clinical scoring system from 1 to 5 (Healy et al., 2013) and
subjected to euthanasia as soon as they progressed beyond clinical
score 1. Brains of mice were tested by FAT. To investigate the
virulence of IKOV, four groups of five OF1 mice were challenged with
either neat TCSN (high dose, neat 104.8 TCID50 ml
21) or a 10-fold
dilution (low dose 103.8 TCID50 ml
21) by either IC or IM
inoculation, followed by twice daily observation and euthanasia when
clinical score progressed beyond 1. IHC demonstration of RABV
antigens in post-mortem samples from brains of mice was performed
as described previously (Hicks et al., 2009).
To assess protection provided by vaccination, a group of 19, 4-week-
old OF1 mice were vaccinated with 0.5 ml of a commercially available
vaccine (VERORAB, Sanofi Pasteur MSD) by intraperitoneal
injection, as standard. A group of five control mice were left
unvaccinated. After 21 days a blood sample was taken from the tail
vein of each mouse and the level of RABV neutralizing antibodies was
assessed using a CVS pseudotype assay (Wright et al., 2009). The mice
were then challenged IC with IKOV TCSN at 104.8 TCID50 ml
21,
D. L. Horton and others
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observed twice daily and subjected to euthanasia at the first sign of
disease.
Molecular analyses. Nucleic acids were extracted using Trizol
(Invitrogen) according to the manufacturer’s instructions. A pan-
lyssavirus real-time PCR assay using iScript (Bio-Rad) was then used
to test for the presence of lyssavirus RNA in mouse brain (Hayman
et al., 2011).
Phylogenetic analyses. The full genome of IKOV was previously
determined directly from clinical civet brain material using a
combination of next generation sequencing and Sanger sequencing
methods (GenBank accession number JX193798; Marston et al., 2012b).
In this report, concatenated gene sequences for all genes
(N+P+M+G+L) from representatives from all lyssavirus species
were compared to those of IKOV using neighbour-joining analysis,
thereby avoiding the potential issue of different evolutionary rates
between genes. Complete concatenated sequences were aligned using the
CLUSTAL W algorithm in MEGA version 4, a neighbour-joining tree was
constructed using p-distances with 1000 boostrap replicates, and
visualized using FigTree(v1.2).
Field sampling of bats in Africa. To investigate the possibility of a
local bat reservoir for IKOV, after ethical review and under permit
from local authorities, bats were sampled both in the immediate
vicinity of the index IKOV case, and in areas of human habitation
(Bunda town and Fort Ikoma village) close to the north-western
border of the SNP in Tanzania (n542) in July 2012. Sera were also
analysed from bats sampled in multiple locations in Southern Kenya
(n5441) as part of a separate study (Table S2). All 483 serum samples
from at least 11 bat species were tested for the presence of neutralizing
antibodies to IKOV using mFAVN and modified rabies fluorescent
focus inhibition test (see Methods section in the online
Supplementary Material).
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